CytomX Therapeutics Inc (NASDAQ:CTMX) insider Sean A. Mccarthy sold 6,526 shares of the business’s stock in a transaction on Friday, January 5th. The shares were sold at an average price of $25.01, for a total value of $163,215.26. Following the completion of the sale, the insider now owns 11,169 shares in the company, valued at $279,336.69. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
Shares of CytomX Therapeutics Inc (NASDAQ:CTMX) opened at $24.96 on Thursday. CytomX Therapeutics Inc has a one year low of $10.64 and a one year high of $25.60. The stock has a market capitalization of $958.68 and a price-to-earnings ratio of -15.90.
Several large investors have recently added to or reduced their stakes in CTMX. Legal & General Group Plc raised its stake in shares of CytomX Therapeutics by 28.6% during the 2nd quarter. Legal & General Group Plc now owns 6,448 shares of the biotechnology company’s stock valued at $101,000 after purchasing an additional 1,434 shares during the period. Macquarie Group Ltd. bought a new stake in shares of CytomX Therapeutics during the 3rd quarter valued at $107,000. Cubist Systematic Strategies LLC bought a new stake in shares of CytomX Therapeutics during the 2nd quarter valued at $174,000. Voya Investment Management LLC bought a new stake in shares of CytomX Therapeutics during the 2nd quarter valued at $203,000. Finally, Nationwide Fund Advisors raised its stake in shares of CytomX Therapeutics by 39.4% during the 2nd quarter. Nationwide Fund Advisors now owns 16,365 shares of the biotechnology company’s stock valued at $254,000 after purchasing an additional 4,622 shares during the period. Institutional investors own 63.13% of the company’s stock.
About CytomX Therapeutics
CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.
Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.